Korean Regulatory Post Marketing Surveillance for Somavert

Launched by PFIZER · Nov 10, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a medication called Somavert, which is used to treat a condition known as acromegaly. Acromegaly is a hormonal disorder that results from excess growth hormone, leading to enlarged bones and tissues. The trial is designed to gather information about how well Somavert works and any potential side effects in patients who are already taking it, as required by Korean health authorities.

To participate in this study, you need to be someone who has been prescribed Somavert based on your doctor's judgment and the local guidelines in Korea. However, if you have certain medical conditions that make Somavert unsafe for you, you won't be able to join. If you do participate, you can expect to be monitored for your health while continuing your regular treatment, helping researchers understand more about Somavert in a real-world setting. This study is currently looking for participants aged 65 to 74, and it welcomes individuals of any gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients who have been prescribed as per local label and investigators' judgement under the setting of routine practice in Korea who are eligible.
• Exclusion Criteria:
• • Patients who are contraindicated for Somavert